林氏和血通痹方熏蒸外洗防治化疗所致周围神经病变的临床疗效观察  

Clinical Observation on the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy by Lin’s Hexue Tongbi Prescription

作　　者：陈壮忠[1,2] 冯婧宇 苏浩东 孙玲玲[1,2] 陈汉锐[1,2] 林丽珠[1] CHEN Zhuangzhong;FENG Jingyu;SU Haodong;SUN Lingling;CHEN Hanrui;LIN Lizhu(Guangzhou University of Chinese Medicine,Guangzhou 510405,China;The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,China;Shenzhen Bao’an Traditional Chinese Medicine Hospital,Shenzhen 518101,China)

机构地区：[1]广州中医药大学,广东广州510405 [2]广州中医药大学第一附属医院,广东广州510405 [3]深圳市宝安区中医院,广东深圳518101

出　　处：《基层中医药》2023年第7期12-20,共9页Basic Traditional Chinese Medicine

基　　金：广东省中医药局项目(20202054);广州中医药大学第一附属医院创新强院治未病项目(2019ZWB10)。

摘　　要：目的 观察林氏和血通痹方防治奥沙利铂和/或紫杉醇类药物化疗所致周围神经病变(CIPN)的临床疗效。方法 选取2021年9月—2022年9月于广州中医药大学第一附属医院住院治疗的以奥沙利铂和/或紫杉醇类药物为基础化疗的恶性肿瘤患者98例,采用最小化动态随机法将患者分为对照组和观察组,各49例。对照组行周围神经病变预防宣教;观察组在对照组的基础上加用林氏和血通痹方熏蒸外洗干预,21 d为1个疗程,持续干预14 d后间隔7 d进入下一疗程。两组均接受4个疗程干预。比较两组每个疗程周围神经病变发生率、周围神经病变相关量表评分以及不良反应发生情况。结果 第4疗程时,观察组周围神经病变发生率低于对照组,差异有统计学意义(P <0.01)。第4疗程时,两组不良事件通用术语标准量表评分差异有统计学意义(P <0.01)。第3疗程和第4疗程时,观察组和对照组的总神经病评分量表和生命质量问题-化疗诱发周围神经病变20项量表评分差异具有统计学意义(P <0.01,P <0.05)。两组不良反应发生情况差异无统计学意义(P> 0.05)。结论 林氏和血通痹方可降低奥沙利铂和/或紫杉醇类药物所致CIPN的发生率。Objective To observe the clinical efficacy of Lin’s Hexue Tongbi Prescription in preventing and treating peripheral neuropathy caused by chemotherapy with oxaliplatin and/or paclitaxel.Methods A total of 98 patients with malignant tumors hospitalized in the First Affiliated Hospital of Guangzhou University of Chinese Medicine from September 2021 to September 2022 were enrolled in this study.The patients were randomized into a control group(n=49)and an observation group(n=49)with the minimization method.The control group received chemotherapy with oxaliplatin and/or paclitaxel combined with neuropathy prevention education.On the basis of the therapy in the control group,the observation group was treated with Lin’s Hexue Tongbi Prescription for external washing.Each course of treatment lasted for 21 days(14 continuous days of treatment and 7 days of withdrawl).Both groups received four courses of treatment.The incidence of peripheral neuropathy,NCI Common Terminology Criteria for Adverse Events(NCI-CTCAE)rating,total neuropathy score(TNS),Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale(QLQ-CIPN20)score,and incidence of adverse reactions were compared between the two groups before and after each course of treatment.Results At the fourth course of treatment,the incidence of peripheral neuropathy in the observation group was lower than that in the control group(P<0.01)and the NCI-CTCAE rating was significantly different between the two groups(P<0.01).At the third and fourth courses of treatment,the TNS and QLQ-CIPN20 score showed significant differences between the two groups(P<0.01,P<0.05).The incidence of adverse reactions had no significant difference between the two groups(P>0.05).Conclusion Lin’s Hexue Tongbi Prescription can reduce the incidence of peripheral neuropathy caused by chemotherapy with oxaliplatin and/or paclitaxel.

关 键 词：林氏和血通痹方 奥沙利铂 紫杉醇类药物 周围神经病变 临床疗效 

分 类 号：R73[医药卫生—肿瘤]